Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Companion animal trials to help human patients
Professor Wouda
The study focuses on dogs because of the similarities between their cancers and human cancers.

Researchers test innovative treatment options 

Clinical trials to treat cancers in cats, dogs, and other companion animals are underway at Kansas State University.

Raelene Wouda, assistant professor of clinical sciences, is offering groundbreaking new treatments to pet owners at a reduced cost.

In addition to improved diagnostic testing and monitoring approaches, the trials include innovative treatment options including combination chemotherapy, t-cell transfer and nanoparticle drug formulations.


As well as improving outcomes for veterinary patients, Wouda hopes the research will provide important information for how the disease can be better diagnosed, monitored and treated in humans.


“For many pet owners, cancer is a terminal diagnosis for they beloved family member,” Wouda said. “These studies provide an opportunity to trial a cutting-edge therapy for their pets at a reasonable price.”

“Moreover, owners participating in these clinical trials take comfort and are pleased to know that they are helping to achieve better treatments and outcomes for pets that may be diagnosed with cancer in the future.”

Professor Wouda’s research, published in the journal Veterinary Comparative Oncology, has been described as a ‘crucial step’ towards a long-term cure for many cancers.

The study focuses on dogs because of the similarities between their cancers and human cancers, like melanoma, lung cancer and osteosarcoma.


Dogs also live with us and are exposed to the same environmental factors, explained Wouda. Furthermore, because dogs age faster than humans, their disease progresses faster, which is a practical advantage for evaluating the efficacy and clinical benefits of new treatments.

"We get clinical answers more quickly in dogs," Wouda said. "The benefit of a particular therapy becomes evident in dogs more rapidly compared to people, and because of this we can preserve research and development finances, but more importantly, we save valuable time and resources."

Professor Wouda will work with graduate students, oncology technicians and referral veterinary surgeons to conduct the clinical trials.

She will also collaborate with human medical researchers to discuss how the research can be best applied to the field of human oncology.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
BSAVA publishes fifth Manual of Canine and Feline Neurology

The BSAVA has published the fifth edition of its BSAVA Manual of Canine and Feline Neurology.

The new edition has been reviewed and updated, including new developments in diagnostics, therapeutic approaches and clinical decision-making. It is structured to support clinicians through diagnosis, treatment and long-term management.

The guide features five new chapters covering acute myelopathies, chronic myelopathies, emergency protocols, neurotoxicology and neuro-oncology.

It also includes over 100 videos, including demonstrations of neurological examinations, clinical presentations and diagnostic procedures.

Nicola Lloyd, publishing manager, said: "Whether you're a general practitioner seeking practical guidance, or a specialist aiming to refine your expertise, this edition remains an indispensable reference for anyone involved in the care of neurologically compromised dogs and cats."